WO2012157790A1 - Composition containing ginseng berry extract for activating mitochondria - Google Patents

Abstract

The present invention relates to a composition for activating mitochondria, and more specifically, to a composition for activating mitochondria containing a ginseng berry extract for increasing the activity of a related enzyme and the amount of DNA in the mitochondria, enhancing muscular strength, and accelerating recovery from fatigue.

Description

Composition for Mitochondrial Activation Containing Ginseng Fruit Extract

The present invention relates to a composition for mitochondrial activation, and more particularly, by containing ginseng fruit extract as an active ingredient, mitochondrial activation, which increases the activity of mitochondrial-related enzymes and the amount of mitochondrial DNA, strengthens muscle strength and promotes fatigue recovery. It relates to a composition for.

Mitochondria are intracellular organelles present in most eukaryotic cells and have their own mitochondrial DNA (mtDNA), which is separated from nuclear DNA.

The main function of mitochondria is to produce ATP, an intracellular energy source. ATP is produced in the electron transport system using NADH, FADH2, which is produced through the TCA circuit in the substrate of the mitochondria. The ATP thus produced is used to drive various energy-required biosynthesis and various metabolic activities.

In addition, mitochondria store calcium ions in the substrate, which play an important role in intracellular signal transduction, and also supply the cytoplasm when necessary. In addition, it is known to play a role in regulating cell death, proliferation and metabolism.

Moreover, unlike nuclear DNA of cells, mtDNA does not have its own repair mechanism and is relatively fragile because there is no histone protein that protects DNA. The damage of mtDNA is known to be closely related to the development of mitochondrial disease, leading to a decrease in the function of mitochondria, reducing the synthesis of ATP, which is an energy source necessary for cell activity, and causes various diseases.

Therefore, the inventors of the present invention, the ginseng fruit extract of the ground part of ginseng increases the activity of mitochondrial-related enzymes and mitochondrial DNA, activates the mitochondria, decreases the mitochondrial membrane potential, NAD due to different components and composition than the general ginseng and red ginseng ^The present invention was completed by increasing the ratio of ⁺ / NADH and inhibiting mitochondrial DNA damage caused by UV irradiation, thereby enhancing muscle strength and promoting fatigue recovery.

It is therefore an object of the present invention to provide a composition for mitochondrial activation.

In order to achieve the above object, the present invention provides a composition for activating mitochondria containing ginseng fruit extract as an active ingredient.

Significantly increased the copy number of mitochondrial DNA for mitochondrial activation according to the present invention, strengthened muscle strength, decreased mitochondrial membrane potential, increased NAD ⁺ / NADH ratio and damaged mitochondrial DNA by UV irradiation Inhibited.

Through this, the composition according to the present invention can be effectively applied for the purpose of prevention and treatment of diseases, for example, degenerative diseases or Parkinson's disease, which are associated with a decrease in mitochondrial function.

1 is a graph showing the results of measuring mitochondria using flow cytometry after each test material was treated to C2C12 cells differentiated into muscle cells.

Figure 2 is a graph showing the results of mitochondria membrane potential (mitochondria membrane potential) measurement.

Figure 3 is a graph showing the results of quantifying the NAD ⁺ / NADH ratio in human skin fibroblasts.

Figure 4 is a graph showing the results of measuring the degree of mitochondrial DNA damage by ultraviolet irradiation.

5 is a graph showing the treadmill exercise time until exhaustion of the intake groups of Example 1 and Comparative Examples 1,2.

The present invention relates to a composition for mitochondrial activation containing ginseng fruit extract as an active ingredient.

The ginseng fruit extract included in the composition according to an embodiment of the present invention may be an extract including the pulp and fruit of the ginseng fruit by removing the seed from the ginseng fruit, or may be an extract containing only the pulp of the ginseng fruit. It may also be an extract containing only the skin of the ginseng fruit.

The ginseng fruit extract may be prepared by extracting with water or lower alcohol, for example methanol, ethanol, for example, is not limited to the extraction method, using the extraction method of natural products commonly used in the food field Of course, it can be obtained by.

Ginseng fruit extract, ginseng fruit rind extract, ginseng fruit pulp extract included in the composition according to an embodiment of the present invention increased the copy number of mitochondrial DNA and promoted fatigue recovery. It also reduced mitochondrial membrane potential, increased NAD ⁺ / NADH ratio, and inhibited mitochondrial DNA damage by UV irradiation.

In one embodiment of the present invention, the ginseng fruit extract, the ginseng fruit extract, and the ginseng fruit extract are included in the composition, various degenerative diseases, brain diseases, neurological diseases, heart diseases, liver diseases, kidneys associated with decreased mitochondrial activity. It may be a composition for preventing or treating diseases, pancreatic diseases or muscle diseases. In addition, the composition of the present invention may be a composition for fatigue recovery.

The degenerative disease is not particularly limited, but may be, for example, degenerative arthritis, rheumatoid arthritis or osteoarthritis. These diseases may be caused by increased expression of inflammation-related factors such as COX-2 (Cyclooxygenase-2) in chondrocytes when mitochondrial activity is reduced.

The brain disease is not particularly limited, but may be, for example, Parkinson's disease, developmental delay, neuropsychiatric disorder, autism, mental retardation, seizure or stroke. These diseases can occur when free radicals caused by the deactivation of mitochondria increase the production of amyloid, a major cause of brain disease, particularly dementia, and accumulate in the body.

The neurological disease is not particularly limited, but may be, for example, ptosis, optic nerve atrophy, strabismus, retinal pigmentosa, blindness, hearing loss, ocular muscle palsy, decreased reflex, fainting, nerve pain or autonomic ataxia.

The heart disease is not particularly limited, but may be, for example, heart attack or cardiomyopathy. These diseases can be caused by overloading of calcium ions or oxidative stress, which can lead to heart function problems when mitochondrial activity is reduced.

The liver disease is not particularly limited, but may be, for example, hypoglycemia or liver failure.

The kidney disease is not particularly limited, but may be, for example, renal tubuloacidosis. These diseases can be caused when the mitochondrial activity is reduced, if the mitochondrial respiratory system is damaged, the oxidative stress increases.

The pancreatic disease is not particularly limited, but may be, for example, pancreatic exocrine dysfunction or parathyroid deficiency.

The muscle disease is not particularly limited, but may be, for example, irritable bowel syndrome, myalgia, muscular dystrophy, gastroesophageal reflux disease, hypotension, convulsions, dyskinesia, constipation or diarrhea. These diseases may occur when mitochondrial activity decreases, affecting the normal movement of muscles while inhibiting the production of ATP, which is an energy source in the body.

The composition for mitochondrial activation according to the present invention is not particularly limited in its formulation, but may be, for example, a pharmaceutical composition or a health food composition.

When the composition according to the present invention is a pharmaceutical composition, it can be used by formulating in the form of oral dosage form, external preparation, suppository, and sterile injectable solution according to a conventional method.

Moreover, 1 type, or 2 or more types of the following additives can be added and mix | blended with the said composition as needed. As said additive, For example, various fruit juices, such as grapefruit, an apple, an orange, a lemon, a pineapple, a banana, a pear, may be concentrated juice, powder juice, etc .; Vitamins (remicol retinol, riboflavin, pyridoxine, cyanocobalamine, sodium ascorbate, nicotinic acid amide, calcium pantothenate, folic acid, biotin, cholecalciferol, cholinergic acid choline, tocopherol or β Water-soluble and fat-soluble vitamins such as carotene); Flavors (such as lemon flavors, orange flavors, strawberry flavors, grapefruit flavors or vanilla essences); Amino acids, nucleic acids and salts thereof (glutamic acid, sodium glutamate, glycine, alanine, aspartic acid, sodium aspartate, inosinic acid, etc.); Plant fibers (polydextrose, pectin, xanthan gum, glucomannan or alginic acid, etc.); Or minerals (sodium chloride, sodium acetate, magnesium sulfate, potassium chloride, magnesium chloride, magnesium carbonate, calcium chloride, dipotassium phosphate, monosodium phosphate, calcium glycophosphate, ferrous citrate, ammonium ferric citrate, iron citrate, manganese sulfate, Copper sulfate, sodium iodide, potassium sorbate, zinc, manganese, copper, iodine or cobalt, and the like.

The composition may further contain pharmaceutical adjuvants such as preservatives, stabilizers, emulsifiers or emulsifiers, salts and / or buffers for the control of osmotic pressure and other therapeutically useful substances, and can be used in various oral forms according to conventional methods. Or in parenteral dosage forms.

Oral formulations include, for example, tablets, pills, hard and soft capsules, solutions, suspensions, emulsifiers, syrups, granules, etc. These formulations may contain diluents (e.g., lactose, dextrose, sucrose, Mannitol, sorbitol, cellulose and glycine), lubricants such as silica, talc, stearic acid and its magnesium or calcium salts and polyethylene glycols. Tablets may further contain binders such as magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and polyvinylpyrrolidine, optionally starch, agar, alginic acid or its sodium salt Pharmaceutical additives such as disintegrants, absorbents, colorants, flavors, and sweeteners. Tablets may be prepared by conventional mixing, granulating or coating methods. Also representative of formulations for parenteral administration are injectable formulations, preferably aqueous isotonic solutions or suspensions.

In addition, when the composition according to the present invention is a health food composition, for example, it can be formulated into various foods, beverages, gums, teas, vitamin complexes or health functional foods. The ginseng fruit used in the present invention has little toxicity and side effects, so it can be used safely even when taken for a long time for the purpose of prevention.

The health food composition of the present invention is not particularly limited to other ingredients except the ginseng fruit extract as an essential ingredient in the indicated ratio, and may contain various flavors or natural carbohydrates as additional ingredients, such as ordinary drinks. Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and other disaccharides such as maltose, sucrose and the like and conventional sugars such as polysaccharides such as dextrin, cyclodextrin, and xylitol Sugar alcohols such as sorbitol and erythritol. As flavoring agents other than those mentioned above, natural flavoring agents (tauumatin, stevia extract (for example, rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used. The proportion of natural carbohydrates is generally about 1-20 g, preferably about 5-12 g per 100 ml of the composition of the present invention.

In addition to the above, the composition of the present invention includes various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, colorants and flavor enhancers, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloids. Thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols or carbonation agents used in carbonated beverages; The compositions of the present invention may also contain pulp for the production of natural fruit juices and fruit juice beverages and vegetable beverages. These components can be used independently or in combination. The proportion of such additives is not so critical but is usually chosen in the range of 0 to 20% by weight, based on the total weight of the composition of the present invention.

Dosage of the ginseng fruit extract, ginseng fruit rind extract, ginseng fruit pulp extract may be limited within the level of those skilled in the art, the daily dosage of the composition according to the present invention is less than the progress of the subject to be administered Depends on a variety of factors, such as onset, age, health status, complications, etc., but on the basis of an adult, generally from 1 to 500 mg / kg, preferably 30 to 200 mg / kg may be administered by dividing 1 to 2 times a day, and the dosage does not limit the scope of the present invention in any way.

The content of the ginseng fruit extract, the skin extract of ginseng fruit, the flesh extract of ginseng fruit is not particularly limited, but is preferably contained in the range of 10 to 90% by weight based on the total weight of the composition. The ginseng fruit extract may be prepared in consideration of the fact that the content of the powder and the functional ingredient may be 10-60% in the manufacture of tablets and soft capsules, and the content of the powder and the functional ingredient may be 10-90% in the manufacture of hard capsules. A health food composition or a pharmaceutical composition containing at -90% can be provided.

Hereinafter, the content of the present invention will be described in more detail through examples and test examples. These examples are provided only for understanding the contents of the present invention, and the scope of the present invention is not limited to these examples, and modifications, substitutions, and insertions commonly known in the art may be performed. This is also included in the scope of the present invention.

Example 1 Preparation of Ginseng Fruit Extract

1) Ginseng fruit pretreatment: Raw ginseng fruit was harvested, seed was separated and removed, and then the ginseng fruit dried raw material was prepared by sun drying or hot air drying.

2) Preparation of ginseng fruit extract: 3 g of water was added to 1 kg of dried ginseng fruit extract to extract reflux, and then filtered and concentrated under reduced pressure at 40 to 45 ° C. to obtain 300 g of ginseng fruit extract.

Example 2 Preparation of Skin Extract of Ginseng Fruit

Only peeled skin from the ginseng fruit, was prepared in substantially the same manner as the production method of the ginseng fruit extract of Example 1 to obtain a skin extract of ginseng fruit.

Example 3 Preparation of a pulp extract of ginseng fruit

Only peeled skin from the ginseng fruit, was prepared in substantially the same manner as the production method of the ginseng fruit extract of Example 1 to obtain a skin extract of ginseng fruit.

[Comparative Examples 1 and 2] Ginseng Root and Red Ginseng Extract

3 g of water was added to 1 kg of ginseng root and red ginseng to extract reflux, and then filtered and concentrated under reduced pressure at 40 to 45 ° C. to prepare ginseng root and red ginseng extract.

<Ginsenoside (Ginseng Saponin) Analysis of Ginseng Fruit and Ginseng Root>

In Example 1 and Comparative Example 1, respectively, ginseng fruit and ginseng root extract were prepared, and then, the extracts were treated with ether to remove fat-soluble components, followed by extracting and concentrating ginsponin with butanol (BuOH). Cenoside component analysis was performed, and the results are shown in Table 1 below.

Table 1 division Example 1 Comparative Example 1 Irradiated Phonine Content (Dry Weight) 33.42% 16.70% PD / PT ratio 0.73 3.23

The ginseng fruit extract prepared in Example 1 had about twice the content of the ginseng root extract prepared in Comparative Example 1 in the content of irradiated phonynin, and ginsenosides were PD (Protopanaxadiol)-"ginsenoside Rb1, Rb2. And Rc and Rd "and PT (Protopanaxatriol)-" Ginsenoside Re, Rg1 and Rg2 "ratios were 0.73 and 3.23, respectively. .

Mineral Analysis of Ginseng Fruit Extract

In order to distinguish that the ginseng fruit extract prepared in Example 1 has the characteristics of 'fruit' different from ginseng, mineral components including vitamins were analyzed, and the results are shown in Table 2 below.

TABLE 2 ingredient content ingredient content Potassium (mg / 100 g) 5865.57 Magnesium (mg / 100 g) 354.38 Calcium (mg / 100 g) 819.26 Zinc (mg / 100 g) 178.49 Iron (mg / 100 g) 59.31 Vitamin A (μ / 100 g, RE) 213.11 Phosphorus (mg / 100 g) 187.17 Vitamin B1 (mg / 100 g) 12.29 Vitamin B2 (mg / 100 g) 8.45 Vitamin B6 (mg / 100 g) 10.50 Vitamin C (mg / 100 g) 4.91 Vitamin E (mg / 100 g, α-TE) 23.61 Vitamin K (mg / 100 g) 232.12 Niacin (mg / 100 g, NE) 5.76 Pantothenic Acid (mg / 100 g) 5.87 Folic acid (μ / 100 g) 349.97

As described above, the ginseng fruit used in the present invention contains more ginseng saponin than the ginseng root, and at the same time, the composition of the saponin is opposite to that of the ginseng root. Could confirm.

Hereinafter, in the present invention, the effect of ginseng fruit extract according to the present invention on mitochondrial production was analyzed through an in vitro experiment.

Test Example 2 Effect on the Number of Mitochondria

(1) Cultivation and Differentiation of C2C12 Cells

C2C12 is a mouse derived cell and was purchased from ATCC. C2C12 cells were cultured in Dulbecco modified eagle's medium (DMEM) of 4.5 g / L glucose with 10% fetal bovine serum, 1% penicillin / streptomycin. When the cell density in the culture plate reaches 95-100%, the culture medium is exchanged with 4.5 g / L DMEM containing 2% horse serum and 1% penicillin / streptomycin to differentiate into muscle cells. It erupted for about 5 days.

(2) mitochondrial water measurement

50 μM of resveratrol, a positive control group, ginseng fruit extract of Example 1, rind extract of ginseng fruit of Example 2, and pulp extract of ginseng fruit of Example 3 on C2C12 cells differentiated into muscle cells 100 mg / ml and 50 μM each of ginsenosides Rg, Rb and Re were treated for 24 hours. The next day, washed three times with PBS, stained with 25 nM mitotracker Red (Molecular Probes, Invitrogen) for 30 minutes at 37 ℃ to measure the amount of mitochondria was measured using a flow cytometry (flow cytometry). The results are shown in FIG.

In the results of Figure 1, the number of mitochondria increased significantly in the group treated with ginseng fruit extract, especially the group treated with the pulp extract of ginseng fruit mitochondria number significantly compared to the group treated with ginsenoside Rg, Rb and Re It increased, and remained at the same level as the positive control resveratrol.

[Test Example 3] Effect of mitochondrial membrane potential (mitochondria membrane potential)

Human dermal fibroblast cells were dispensed at 1.0 × 10 ⁵ per well into a 96-well black plate for fluorescence measurement and 37 ° C., 5% CO using DMEM (FBS 10%) medium containing penicillin / streptomycin. After culturing for 1 day at ₂ conditions, each sample (Trolox 1 and 10 ppm, ginseng fruit extract of Example 1 0.1, 1 and 10 ppm) was treated. DMEM (no FBS) added with penicillin / streptomycin was used as a medium for sample treatment, and cultured for 1 day at 37 ° C. and 5% CO ₂ . The test group was washed after treating with H ₂ O ₂ at a concentration of 500 μM for 90 minutes. Ix PBS buffered saline (Sigma Co.) was used for washing. After washing, insert the test sample and incubate for 72 hours, wash with PBS to remove the remaining medium, add the appropriate amount of PBS, and then treated with UVA (5 J / ㎡) and UVB (30 mJ / ㎠), respectively, containing the sample The prepared medium was incubated for 24 hours at 37 ℃, 5% CO ₂ conditions. After culturing, the medium was removed by HCSS, and 10 μg / ml of JC-1 was added thereto, followed by incubation for 20 minutes at 37 ° C. and 5% CO ₂ . After culturing, washing with HCSS, adding appropriate amount of HCSS, and comparing the membrane potentials by measuring the fluorescence intensity with a fluorescence plate reader (Ex = 485 nm, Em = 530 nm green / Ex = 530 nm, Em = 590 nm red). Is shown in FIG. 2.

In the results of Figure 2, it was confirmed that the mitochondrial membrane potential reduction by H ₂ O ₂ in the group treated with ginseng fruit extract recovers 20 to 35% or more. This means activation of the cell, which means that the potential for ATP production is increased.

Test Example 4 Effect on NAD ⁺ / NADH ratio

Human skin fibroblasts were aliquoted into ⁵ wells for fluorometry at ^5.0 × 10 ⁵ per well and incubated at 37 ° C., 5% CO ₂ for 1 day using DMEM (10% FBS) medium supplemented with penicillin / streptomycin. Each sample (Ginseng Fruit Extract 1, 3, 10 and 100 ppm) was then treated. DMEM (no FBS) added with penicillin / streptomycin was used as a medium for sample treatment, and cultured for 1 day at 37 ° C. and 5% CO ₂ . 1 × PBS buffered saline (Sigma Co.) was used for washing. After washing, the test sample was added, cultured for 72 hours, washed with PBS to remove the remaining medium, and quantified using NAD ⁺ / NADH ratio analysis kit (ab65348, abcam), and the results are shown in FIG. 3.

In the results of Figure 3, it was confirmed that the NAD ⁺ / NADH ratio of fibroblasts in the group treated with ginseng fruit extract increased by more than 150-200%. This increase in NAD ⁺ / NADH ratio can thereby increase the activity of deacetylase, such as SIRT1.

Test Example 5 Inhibition of Mitochondrial DNA Mutation Induced by UV Irradiation

1) Culture and Treatment of NHDF Cells

The cell lines used in the experiments were human dermal dermal tissue cells, which were purchased from ATCC. Normal Human Dermal Fibroblast (NHDF) cells were cultured in 4.5 g / L DMEM containing 10% fetal bovine serum (FBS), 1% penicillin / streptomycin. After dispensing 5.0 × 10 ⁴ per well into 6-well plates and incubating for one day at 37 ° C. and 5% CO ₂ , the medium was replaced with DMEM containing 1% bovine serum and left for 4 hours. Thereafter, the ginseng fruit extract was treated with cells at a concentration of 100 ppm for one day, washed with PBS to remove the remaining medium, and 1 ml of 1 × PBS was dispensed to obtain UVB (50 mJ / cm 2) for each experimental condition. It was treated with and used for the experiment after one day incubation.

2) Restoration of mitochondrial DNA damage by UV irradiation

Ultraviolet irradiated cells were washed with 1 × PBS and genomic DNA was extracted using FastPure ^™ DNA kit (Takara). 5 ng of the extracted DNA was subjected to quantitative real-time PCR using iQ ^™ SYBRGreen Supermix (Bio-Rad) and the primers described in Table 3 below.

TABLE 3 name Primer Sequence 3,895 bp deletion (548-4443 nt in mitochondrial DNA) Sense primer 5'-GCTTCTGGCCACAGCACTTA-3 '(SEQ ID NO: 1) Antisense primer 5'-TAGCGCTGTGAT GAGTGTGC-3 '(SEQ ID NO: 2) 83 bp conserved region of mitochondrial DNA Sense primer 5'-GATTTGGGTACCACCCAAGTATTG-3 '(SEQ ID NO: 3) Antisense primer 5'-AATATTCA TGGTGGCTGGCAGTA-3 '(SEQ ID NO: 4)

PCR amplification was performed under the condition that the cells were denatured at 95 ° C for 3 minutes, denatured at 95 ° C for 30 seconds, annealed at 60 ° C for 30 seconds, and extended at 72 ° C for 30 seconds, and then expanded at 72 ° C for 10 minutes The result was obtained through a method (comparative cycle threshold method), and the results are shown in FIG. 4.

In the results of Figure 4, it was confirmed that the mitochondrial 3,895 bp deletion damage was increased by 53% by ultraviolet irradiation was reduced by 12% by the ginseng fruit extract.

Test Example 5 Strength Measurement

32 male 5-week-old rats (rat: Sprague-Dawley) were fed from a central laboratory animal and pre-bred for 1 week with solid blended feed (Samyang oil feed). Untreated control group, positive control glutamine intake group, red ginseng extract and ginseng fruit extract intake group) and water and feed were fed freely.

The environment of the animal feeding room maintained a 12-hour light-dark cycle at a temperature of 23 ± 1 ° C, a humidity of 50 ± 5 and a 12 hour interval, and the dietary intake and weight gain were constant once a week. Measured at time. The diet used in the experiment was based on AIN-93G, and glutamine, red ginseng extract of Comparative Example 2 and ginseng fruit extract of Example 1 were added 30 g per kg of feed (3% of the total diet weight), respectively. The total weight of the diet was adjusted in the amount of starch and protein, and the details of other experimental diets are shown in Table 4. Table 4 shows the animal test diet composition by AIN-93.

Table 4 ingredient AIN-93 (g / kg) Control Glutamine Red Ginseng Extract Ginseng Fruit Extract Corn starch 368 368 368 338 338 Dextrinized Corn Starch 132 132 132 132 132 Sucrose 100 100 100 100 100 casein 200 200 170 200 200 L-cysteine 3 3 3 3 3 Soybean oil 100 100 100 100 100 Mineral mix 35 35 35 35 35 Vitamin mix 10 10 10 10 10 Cellulose powder 50 50 50 50 50 Choline Hydrogen Tartrate 2.5 2.5 2.5 2.5 2.5 t-butylhydroquinone 0.014 0.014 0.014 0.014 0.014 Functional ingredient - - 30 30 30 Sum 1,000 1,000 1,000 1,000 1,000

All groups performed strength measurements once a week. The measurement method was carried out by modifying the method of Smith et al., The results are shown in FIG. Maximum strength was determined when the rat lays a horizontal bar, and the numerical value was then displayed through a digital force gauge.

In the results of Figure 5, the ginseng fruit extract according to the present invention showed a significant level of strength improvement over time, even compared to the positive control glutamine showed an equal or greater strength improvement effect.

Formulation Example 1 Preparation of Soft Capsule

80 mg of ginseng fruit extract of Example 1, vitamin E 9 mg, vitamin C 9 mg, palm oil 2 mg, vegetable hardened oil 8 mg, lead 4 mg and lecithin 9 mg were mixed and mixed according to a conventional method to fill the soft capsule A liquid was prepared. 400 mg per capsule was filled to prepare a soft capsule.

Apart from the above, a soft capsule sheet was prepared at a ratio of 66 parts by weight of gelatin, 24 parts by weight of glycerine, and 10 parts by weight of sorbitol solution and filled with the filler to prepare a soft capsule containing 400 mg of the composition according to the present invention.

Formulation Example 2 Preparation of Tablet

Ginseng fruit extract of Example 1 80 mg, vitamin E 9 mg, vitamin C 9 mg, galactooligosaccharide 200 mg, lactose 60 mg and malt sugar 140 mg were mixed and granulated using a fluidized bed dryer and then sugar ester 6 mg was added. Tablets were prepared by compression of 504 mg of these compositions in a conventional manner.

Formulation Example 3 Preparation of Drink

80 mg of ginseng fruit extract of Example 1, 9 mg of vitamin E, 9 mg of vitamin C, 10 g of glucose, 0.6 g of citric acid, and 25 g of liquid oligosaccharide were mixed, and then 300 ml of purified water was added to each bottle to 200 ml. It was. After filling the bottle sterilized for 4 to 5 seconds at 130 ℃ to prepare a beverage.

Formulation Example 4 Preparation of Granules

80 mg of ginseng fruit extract of Example 1, 9 mg of vitamin E, 9 mg of vitamin C, 250 mg of anhydrous glucose, and 550 mg of starch were mixed, molded into granules using a fluidized bed granulator, and then filled into fabrics.

SEQ ID NO: 1 is a sense primer for 548-4443 nt in mitochondrial DNA.

SEQ ID NO: 2 is an antisense primer for 548-4443 nt in mitochondrial DNA.

SEQ ID NO: 3 is a sense primer for the 83 bp conserved region of mitochondrial DNA.

SEQ ID NO: 4 is an antisense primer for the 83 bp conserved region of mitochondrial DNA.

Claims (14)

Composition for mitochondrial activation containing ginseng fruit extract as an active ingredient. The method of claim 1, The composition is a composition for mitochondria activation, which is a health food composition or a pharmaceutical composition. The method of claim 1, The active ingredient is a composition for mitochondrial activation comprises 10 to 90% by weight based on the total weight of the composition. The method of claim 1, The ginseng fruit extract is a composition for mitochondrial activation, which is a pulp extract of ginseng fruit, a rind extract of ginseng fruit or a pulp and rind extract of ginseng fruit. Use of the composition of claim 1 for strengthening muscle strength. Use of the composition of claim 1 for the prevention or treatment of degenerative diseases, brain diseases, neurological diseases, heart diseases, liver diseases, kidney diseases, pancreatic diseases or muscle diseases. Use of the composition of claim 1 for the prevention or treatment of Parkinson's disease, developmental delay, neuropsychiatric disorders, autism, mental retardation, seizures or stroke. Use of the composition of claim 1 for the prevention or treatment of ptosis, optic nerve atrophy, strabismus, retinal pigmentosa, blindness, hearing loss, eye muscle paralysis, reflexes, fainting, nerve pain or autonomic ataxia. Use of the composition of claim 1 for the prophylaxis or treatment of heart attack or cardiomyopathy. Use of the composition of claim 1 for the prevention or treatment of hypoglycemia or liver failure. Use of the composition of claim 1 for the prophylaxis or treatment of renal tubuloacidosis. Use of the composition of claim 1 for the prevention or treatment of pancreatic exocrine dysfunction or parathyroidism. Use of the composition of claim 1 for the prevention or treatment of irritable bowel syndrome, myalgia, muscular dystrophy, gastroesophageal reflux disease, hypotension, convulsions, movement disorders, constipation or diarrhea. Use of the composition of claim 1 for fatigue recovery.

Images